The OncotypeDX® breast cancer test is a diagnostic test created to help patients who have been recently diagnosed with early stage, estrogen receptor positive breast cancer. The test gives patients and their doctors more information about their specific tumor and allows them to create a better treatment plan.


The long-awaited results of the Trial Assigning Individualized Options for Treatment (TAILORx) definitively identified a vast majority of women with early stage breast cancer who will receive no benefit from chemotherapy, and the minority for whom chemotherapy can be life-saving.


After a patient is diagnosed with breast cancer, doctors and patients work together to plan the best course of treatment. Along with other pieces of information, the OncotypeDX® breast cancer test can assist in deciding whether or not to make chemotherapy part of their treatment plan. The test can also help doctors determine the likelihood of the cancer returning in the future, also known as recurrence.
The OncotypeDX® breast cancer test works by examining a sample of breast cancer tissue. The test measures a group of breast cancer genes in this sample to see how active they are (also known as how they are expressed). The result of the test is reported as a number between 0 and 100, known as the Recurrence Score result. A lower score means the cancer has a lower chance of returning, and a higher score means that there is a higher chance of the cancer returning. The score also provides patients and doctors with important information regarding the potential benefit of adding chemotherapy to hormonal therapy. A low score indicates that the patient will receive minimal benefit from chemotherapy, whereas a patient with a high score can have significant benefit from chemotherapy. Because everyone's body and tumor are unique, obtaining a Recurrence Score result helps make treatment decisions tailored to the patient.

The OncotypeDX® breast cancer test provides information in addition to standard measurements (such as tumor size, tumor grade and lymph node status) that doctors have traditionally used to estimate how likely a patient's cancer is to return, and to help make treatment decisions.
The Oncotype DX® Breast Recurrence Score has been validated and provides level 1, category B evidence as defined by Simon et al. Consistent results across multiple well-designed studies demonstrate the assay’s robust analytic performance, clinical validity and clinical utility. As a result the assay has been incorporated into multiple guidelines including National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), National Institute for Health and Care Excellence (NICE), St. Gallen, and European Society for Medical Oncology (ESMO).

For more information please visit Oncotype DX®.

Clinical Utility

Prognosis of patients with invasive breast cancer

The Recurrence Score allows patients and physicians to determine the risk of developing a distant metastasis in 10 years for patients with ER+, lymph node 0-3, and HER2 negative, early stage breast cancer patients.

Prediction of chemotherapy benefit

The Recurrence Score provides information on which patient benefits and which does not benefit from the addition of adjuvant chemotherapy to the treatment plan. This way, the treatment of the patient is individualized based on the biology of the tumor.




By testing every eligible patient after surgery, but before you discuss her treatment plan, you can make recommendations with increased insight and confidence


How to order

Our dedicated Client Service Team is committed to answer your questions with regards to the services offered by Genekor. If you would like to order any of the tests that Genekor performs please contact us directly.

Please click here to see the specimen preparation and shipping instructions

If you would like to send us your sample,

contact us in order to arrange for all the logistics.

Please click here

Download Forms

you are already aware of the process of sending a sample, in order to download all the related forms.

Please click here